Cite
MLA Citation
Jonathan Lim et al.. “Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA.” Future oncology, vol. 15, 2019, pp. 1493–1504. http://access.bl.uk/ark:/81055/vdc_100166969481.0x000003